Merck’s Keytruda Further Entrenches Women’s Oncology Position With Cervical Cancer Results

Merck announced results from the Phase III KEYNOTE-A18 study in cervical cancer • Source: Shutterstock
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Clinical Trials

More from R&D